# **PI-103**

## Inhibitor of PI3K & mTOR; Autophagy inducer

Catalog # inh-pi10

# For research use only

Version # 15D03-MM

# **PRODUCT INFORMATION**

Contents:

#### •5 mg PI-103 Storage and stability:

PI-103 is provided lyophilized and shipped at room temperature. Store at -20 °C. Lyophilized PI-103 is stable for 3 years when properly stored.
Upon resuspension, prepare aliquots of PI-103 and store at -20 °C. Resuspended PI-103 is stable for 6 months when properly stored.

## Quality control:

- Purity: ≥97% (UHPLC)

- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) is confirmed using HEK-Blue<sup>™</sup> TLR2 and HEK-Blue<sup>™</sup> TLR4 cells.


# DESCRIPTION

PI-103 is a potent ATP-competitive dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mTOR (mammalian target of rapamycin). PI3K, an important intracellular mediator, regulates multiple cellular functions including cell growth and survival. PI3K activates a number of downstream targets including the serine/threonine kinase Akt that activates mTOR, the master negative regulator of autophagy. By inhibiting mTOR activity, PI-103 induces autophagy and promotes cell survival<sup>1, 2</sup>. Conversely, combining PI-103 with inhibitors of autophagy, such as 3-methyladenine or bafilomycin A1, leads to apoptosis<sup>1</sup>.

1. Fan QW. & Weiss W., 2011. Autophagy and Akt promote survival in glioma. Autophagy7(5): 536-8. 2. Park S. et al., 2008. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.Leukemia. 22(9):1698-706. 3. Aronson LI. et al., 2013. Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application. Leukemia. 27(12):2397-403. 5. López-Fauqued M. et al., 2010. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. Int J Cancer. 126(7):1549-61.

# **CHEMICAL PROPERTIES**

Solubility: 10 mg/ml (28.7 mM) in DMSO Synonym: 3-[4-(4-Morpholinylpyrido[3',2':4,5]furo[3,2-d]pyrimidin-2yl]phenol hydrochloride CAS number: 371935-74-9 Formula: C19H16N4O3 Molecular weight: 348.4 Structure:



TECHNICAL SUPPORT InvivoGen USA (Toll-Free): 888-457-5873 InvivoGen USA (International): +1 (858) 457-5873 InvivoGen Europe: +33 (0) 5-62-71-69-39 InvivoGen Hong Kong: +852 3-622-34-80 E-mail: info@invivogen.com

## **METHODS**

## Preparation of 10 mg/ml (28.7 mM) stock solution

- Add 1 ml of DMSO to 10 mg of PI-103. Mix by vortexing.

- Prepare further dilutions by adding the appropriate amount of endotoxin-free water.

Working concentration: 0.1-10  $\mu$ M (35 ng/ml -3.5  $\mu$ g/ml) for cell culture assays

## PROTOCOLS

For reference only; as described in the indicated publications. <u>Cell Culture Assay</u><sup>2</sup> Cells: Human leukemic cell lines; MOLM14, OCI-AML3 and MV4-11 Working concentration: 0.1-1  $\mu$ M Treatment time: 48 hours

Method: MTS assay (colorimetric assay for assessing cell viability)

## Cell Culture Assay<sup>3</sup>

Cells: Multiple myeloma cell lines; NCI- H929, MM.1S and U266 cells Working concentration:  $1-10 \ \mu mol/L$ 

Treatment time: 24 hours

Method: Acridine orange staining for autophagy detection using confocal microscopy and flow cytometry. Western blotting to detect the autophagosome markers, LC3II.

## Animal Study<sup>5</sup>

Animal model: Myeloma xenograft model in FVB/N mice Dose: 10 mg/kg Administration: Daily intraperitoneal injection for 8 days.

# RELATED PRODUCTS

Product	Description	Catalog Code
Bafilomycin A1	Autophagy inhibitor	tlrl-baf1
Everolimus	Autophagy inhibitor	tlrl-eve
3-Methyladenine	Autophagy inhibitor	tlrl-3ma
Rapamycin	Autophagy inducer	tlrl-rap
Resveratrol	Autophagy inducer	tlrl-resv
Temsirolimus	Autophagy inducer	tlrl-tems

